Skip to content

Total debt at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$445.39M+32.2%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$5.7M-6.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Pfizer logo
PfizerPFE
Johnson & Johnson logo
Johnson & JohnsonJNJ
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

Plus components not separately reported this period.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's total debt?
UroGen Pharma (URGN) reported total debt of $197.09M in Q1 2026.
How has UroGen Pharma's total debt changed year-over-year?
UroGen Pharma's total debt increased by 56.0% year-over-year, from $126.36M to $197.09M.
What is the long-term trend for UroGen Pharma's total debt?
Over 5 years (2020 to 2025), UroGen Pharma's total debt has grown at a 117.1% compound annual growth rate (CAGR), from $2.7M to $130.09M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.